合富中国公告称，公司股票于2025年12月4日、5日及8日连续三个交易日涨幅偏离值累计超20%，属异 常波动。10月28日至12月8日累计涨幅336.83%，16个交易日涨停，6次触及异常波动、3次触及严重异 常波动。截至12月8日，股价29.18元/股创历史新高，静态市盈率421.35倍，远高于行业的28.86倍。 2025年第三季度净利润为 -504.80万元，同比降225.26%。控股股东有减持计划，但截至12月8日尚未减 持，提醒投资者注意风险。 ...

Core Viewpoint - Tongce Medical (600763) has shown a slight decline in stock price and mixed capital flow, indicating potential investor caution and varying interest from different types of investors [1][2]. Group 1: Stock Performance - As of December 8, 2025, Tongce Medical closed at 41.74 CNY, down 0.1% with a turnover rate of 0.7% and a trading volume of 31,500 lots, amounting to a total transaction value of 132 million CNY [1]. - Over the past five days, the stock has experienced fluctuations in price and capital flow, with a notable net outflow of 1,098.88 million CNY on December 8, 2025, which accounted for 8.35% of the total transaction value [2]. Group 2: Financial Metrics - Tongce Medical's total market capitalization is 18.67 billion CNY, with a net asset value of 4.703 billion CNY and a net profit of 514 million CNY, ranking 8th, 12th, and 6th respectively within the medical services industry [3]. - The company reported a year-on-year revenue increase of 2.56% for the first three quarters of 2025, totaling 2.29 billion CNY, with a net profit of 514 million CNY, reflecting a 3.16% increase [3]. Group 3: Institutional Ratings - In the last 90 days, eight institutions have provided ratings for Tongce Medical, with five giving a "buy" rating and three an "increase" rating, while the average target price set by institutions is 52.88 CNY [4].

Group 1 - The company, Gushengtang (02273), announced a share buyback plan on December 8, 2025, involving an expenditure of approximately HKD 6.2216 million to repurchase 220,600 shares [1]

Market Performance - The medical services sector increased by 0.51% on December 8, with Chengdu XianDao leading the gains [1] - The Shanghai Composite Index closed at 3924.08, up 0.54%, while the Shenzhen Component Index closed at 13329.99, up 1.39% [1] Top Gainers in Medical Services - Chengdu XianDao (688222) closed at 23.20, up 1.75% with a trading volume of 45,700 shares and a turnover of 106 million yuan [1] - Other notable gainers include: - Guangzheng Eye Hospital (002524) at 4.63, up 1.54% [1] - MediXis (688202) at 53.96, up 1.35% [1] - WuXi AppTec (603259) at 91.55, up 1.27% with a significant turnover of 3.33 billion yuan [1] Top Losers in Medical Services - ST Zhongzhu (600568) closed at 2.79, down 2.11% with a trading volume of 614,600 shares and a turnover of 173 million yuan [2] - Other notable losers include: - Haoyuan Pharmaceutical (688131) at 74.35, down 1.50% [2] - Aoyang Health (002172) at 4.20, down 1.41% [2] Capital Flow Analysis - The medical services sector experienced a net outflow of 297 million yuan from institutional investors, while retail investors saw a net inflow of 317 million yuan [2][3] - Notable capital flows include: - WuXi AppTec (603259) with a net outflow of 30.81 million yuan from institutional investors [3] - NuoSiGe (301333) with a net inflow of 11.54 million yuan from institutional investors [3]

Core Insights - The forum "Integration and Precision Rehabilitation - 2025 Cancer Rehabilitation Forum" held in Tianjin aims to enhance the quality of life for cancer patients through innovative rehabilitation practices and multidisciplinary collaboration [1][4][5]. Group 1: Event Overview - The forum was organized by the Tianjin Anti-Cancer Association and Baize Medical Group, gathering experts from various fields including oncology, rehabilitation, psychology, and traditional Chinese medicine [1][2]. - The event focused on the integration of cancer rehabilitation within the full-cycle management model, emphasizing the importance of improving patient quality of life alongside survival rates [1][4]. Group 2: Industry Context - The "Healthy China Action (2019-2030)" highlights the significant impact of cancer on public health and stresses the need for rehabilitation treatment [1]. - The "Healthy China Action - Cancer Prevention and Control Implementation Plan (2023-2030)" calls for standardized management of diagnosis and treatment, including rehabilitation guidance and psychological support [1]. Group 3: Company Initiatives - Baize Medical Group aims to establish itself as a leading cancer full-cycle medical group in China, operating six for-profit hospitals and managing two non-profit hospitals [2]. - The group has proposed a comprehensive approach to cancer management, focusing on prevention, screening, diagnosis, treatment, and rehabilitation [5][12]. Group 4: Expert Contributions - Experts at the forum discussed various aspects of cancer rehabilitation, including the role of traditional Chinese medicine and the need for multidisciplinary approaches to address challenges faced by young breast cancer patients [8][9]. - The forum also featured discussions on symptom management and the importance of personalized rehabilitation plans to enhance patient quality of life [9][10]. Group 5: Future Directions - The forum resulted in the formation of the "Cancer Rehabilitation Expert Consensus (2025)," which aims to standardize clinical practices in cancer rehabilitation [12]. - The event served as a platform for collaboration among leading medical institutions, fostering innovation in cancer rehabilitation practices [12][14].

英国国家医疗服务体系（NHS）正在面临一个被长期忽视但影响深远的系统性问题：大量患者在从全科 医生（GP）诊所转诊至医院的过程中被卡在"黑洞"里，最终既未被录入医院的等待名单，也无法获得 所需治疗。 数据分析公司舆观（YouGov）的最新调查显示，英国每7名需要医院诊疗的患者中，就有1人因转诊信 息丢失、延误或被拒而无法进入治疗流程。 转诊"黑洞" 该项调查由英国健康观察组织Healthwatch委托舆观进行，共对2622名在过去一年内经历过GP转诊的成 年人进行了调查。结果显示，14%的转诊从未进入医院系统，患者因此被完全排除在检查或治疗的等待 名单之外。 更令人担忧的是，在这些被困在转诊"黑洞"中的人群中，有3/4的人因等待无果而出现身心健康恶化。 调查同时揭示，英国的医疗沟通极其不可靠，七成患者只有在主动联络NHS，询问为何没有收到进一步 信息时，才得知自己的转诊信息从未成功送达或被医院接收。 在部分案例中，问题出在最初环节——GP诊所虽然同意了转诊，但相关文件并未真正发送出去；也有 案例显示，医院未能正确录入转诊信息。但无论何种原因，这种"信息断裂"正使数以万计的患者陷入治 疗不确定性之中。 Heal ...

| IQ | 南方医科大学第八附属医院 | 三级 | 佛山市顺德区伦敦街道办事处态 | | --- | --- | --- | --- | | | (佛山市顺德区第一人民医院) | | 村村委会甲子路1号 | | | 佛山市南海区人民医院 | | 佛山市南海区狮山镇桂丹路 120 | | 17 | (华南理工大学附属第六医院) | 三级 | ਵੇ | | 18 | 厂东省人民医院南海医院 | 三级 | 佛山市南海区桂城街道 夏东路 23 | | | | | ਵੇ | | 19 | 和祐至臻医院 | 二级 | 佛山市顺德区北溶镇君兰社区和 仁路1号1号楼负1层C区 | | | | | 105-150 号房、5 号楼 | | 20 | 惠州市第一人民医院 | 三级 | 惠州市惠城区北江三新南路 20号 | | | | | 惠州市惠城区鹅岭北路 41 号;惠 | | 21 | 惠州市中心人民医院 | 三级 | 州市惠城区下埔横江四路8号; | | | | | 惠州市仲恺高新区陈江街道胜利 | | | | | 村甲子LED工业园新陈大道北面 | | 22 | 惠阳三和医院 | 三级 | 惠州市惠阳区淡水金惠大道康和 ...

| 17 | 佛山市南海区人民医院 | 三级 | 佛山市南海区狮山镇桂丹路 120 | | --- | --- | --- | --- | | | (华南理工大学附属第六医院) | | ਵੇ | | 18 | 厂东省人民医院南海医院 | 三级 | 佛山市南海区桂城街道夏东路 23 | | | | | s | | 19 | 和祐全续医院 | 二级 | 佛山市顺德区北溶镇君兰社区和 仁路1号1号楼负1层C区 | | | | | 105-150 号房、5号楼 | | 20 | 惠州市第一人民医院 | 三级 | 惠州市惠城区北江三新南路20号 | | | | | 惠州市惠城区鹅岭北路 41 号;惠 州市惠城区下埔横江四路8号; | | 21 | 惠州市中心人民医院 | 三级 | 惠州市仲恺高新区陈江街道胜利 | | | | | 村甲子LED工业园新陈大道北面 | | 22 | 惠阳三和医院 | 三级 | 惠州市惠阳区淡水金惠大道康和 | | | | | 路3号 | | 23 | 东莞市人民医院 | 三级 | 东莞市万江街道万道路 78号 | | 24 | 东莞康华医院 | 三级 | 东莞市南城区东莞大道 1000 号 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 每经记者｜黄宗彦 每经编辑｜吴永久 每经资本眼专栏记者将围绕相关数据进行重点分析。 先看"9A公司"的经营和二级市场表现。 每经资本眼专栏记者从盈利稳定性（公司净利润为正的年份数）、成长性（净利润同比增长的年份数）、二级市场表现（当年股价上涨的年份数、9年平均 复权涨幅）等维度进行统计。 为方便统计和观察公司的年度表现，本文所涉及的业绩及二级市场股价数据，均采用自然年（2016至2024年）来统计。 统计结果显示，"9A公司"盈利稳定性较高，连续9年盈利的公司数达105家，占比90.52%。有113家公司在5年及以上实现盈利，占比97.41%。成长性方面， 有103家公司在5年及以上实现净利润同比增长率为正，占比88.79%。 值得注意的是，二级市场表现与经营表现略有分化：在9年中，有71家公司的股价在5年及以上年份实现上涨，占比61.21%。 在股价涨幅方面，"9A公司"的9年平均涨幅为10.49%，中位数为8.96%（"9A公司"9年期间历年年度涨幅平均数加总再平均）。 连续9次信披评价获评A级有多难？近日，每经资本眼专栏记者收集了沪深两大交易所发布的最近 ...

招银国际环球市场 | 市场策略 | 招财日报 每日投资策略 行业及公司点评 全球市场观察 2025 年 12 月 8 日 1 中国股市上涨，港股原材料、金融与工业领涨，综合、公用事业与必选消费 下跌，南向净买入 13.4 亿港元，小米与美团净买入最多，阿里与腾讯净卖出 居前。A 股非银金融、有色金属与工贸综合涨幅居前，银行、煤炭与电信服 务跑输市场。A 股券商板块大涨，中国证监会主席表示鼓励头部机构通过并 购重组打造国际一流投行，将对优质券商适度松绑打开资本空间与杠杆限制， 鼓励中小机构打造小而美的精品投行、特色投行和特色服务商；保险板块大 涨，保险公司投资资本市场的风险因子再度下调，显示监管机构鼓励险资等 长期资本入市的态度。 美股上涨，通讯服务、信息技术与可选消费涨幅居前，公用事业、能源与医 疗保健跌幅最大。戴尔、联想、惠普等主要 OEM 厂商计划大幅提高服务器 价格，因供应很难跟上快速增长的需求。微软与博通商谈定制芯片设计合作， 可能替换现有供应商 Marvell，以降低对英伟达依赖。随着 AI 产品创新，定 制芯片需求激增，科技公司寻求供应链多元化以降低风险与成本。 美债收益率升至两周新高，美元指数转 ...